Ketamine Depression Study

Clinical research studies investigating club drug Ketamine show promising results in controlling and reducing symptoms.

Major Depressive Disorder, Bipolar Disorder, and PTSD are some of the most painful experiences a person can endure. Each year, one million people choose suicide, rather than fighting through one more day. For many, there is a cure available for depression symptoms in existing drugs and treatments. However, for some people, these treatments do not work. They suffer from a condition called Treatment-Resistant Depression (TRD), which, like the name suggests, means they are resistant to traditional drugs and treatments.

TRD could be caused by a treatment not having the desired effect, unacceptable side effects, or other complications. This type of depression tends to be more severe, especially if the patients do not have a good support system. One potential option doctors and scientists are researching is treating the symptoms through drug induced experiences, or “trips”, rather than drugs alone. Through ongoing clinical research, doctors have found that the club drug Ketamine, when used in very small and controlled doses, can produce an experience that has shown positive results in study participants. Clinical research of Ketamine for depression started over 15 years ago at Yale University. Since then dozens of studies have been conducted by different institutions, including the Veterans Administration and the National Institutes of Health, each time reconfirming the original findings. Ketamine works differently compared to other depression treatments. By briefly blocking neurotransmitters in the brain, rather than manipulating the quantity of them, as existing treatments do, Ketamine has been clinically proven to have fewer side-effects than traditional treatments for TRD. When a patient receives treatment a chain of events occurs in his/her brain, creating new connections and “rewriting” certain areas. Experts believe these new connections allow the patients to break out of negative loops and may enable them to make long lasting behavioral changes. Although Ketamine shows great potential, it is not perfect. The most obvious conflict is

Clinical research of Ketamine for depression started over 15 years ago at Yale University. Since then dozens of studies have been conducted by different institutions, including the Veterans Administration and the National Institutes of Health, each time reconfirming the original findings. Ketamine works differently compared to other depression treatments. By briefly blocking neurotransmitters in the brain, rather than manipulating the quantity of them, as existing treatments do, Ketamine has been clinically proven to have fewer side-effects than traditional treatments for TRD. When a patient receives treatment a chain of events occurs in his/her brain, creating new connections and “rewriting” certain areas. Experts believe these new connections allow the patients to break out of negative loops and may enable them to make long lasting behavioral changes. Although Ketamine shows great potential, it is not perfect. The most obvious conflict is

Although Ketamine shows great potential, it is not perfect. The most obvious conflict is the drug’s history as a club drug, which causes hesitation by the medical community and government. It is also not easily available since it is not, yet, FDA approved. The only way to experience this breakthrough treatment is through clinical research studies. Collaborative Neuro Science Network (CNS) currently has several clinical trials enrolling for multiple indications including:
– TRD
– Depression
– PTSD
– Bipolar Depression
– And Others

Qualified participants may receive investigational study treatment at no cost. Compensation may be offered for time and travel. Breakthrough’s today lead to tomorrow’s treatments!

By | 2017-05-18T11:42:40+00:00 May 18th, 2017|Depression, Uncategorized|0 Comments

About the Author:

Leave A Comment